Roche /Atea Pharmaceuticals collaborate to develop oral COVID-19 treatment

Roche and Atea Pharmaceutical are collaborating to develop, manufacture, and distribute Atea’s investigational oral direct-acting antiviral AT-527, which acts by blocking the viral RNA polymerase enzyme needed for viral replication. It is currently undergoing phase 2 clinical trial for hospitalized patients with moderate COVID-19, with phase 3 clinical trial expected to start in Q1 2021. Besides potentially being an effective oral treatment for hospitalized patients, AT-527 could also be the first oral treatment option for non-hospitalized COVID-19 patients, and could help treat patients early to reduce the progression of the infection. If thez clinical trials are successful and regulatory approvals are granted, Atea will distribute this treatment option in the U.S., with Roche responsible for distribution outside the United States.

Check Also

Can tablets be broken before you take them?

Tablets are the most common form of medicines taken by mankind. I believe none of …

%d bloggers like this: